Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Thursday, February 23, 2023
Although treatment with chimeric antigen receptor (CAR) T-cell therapies has been an effective strategy for patients with heavily pretreated or refractory multiple myeloma, therapeutic options for patients with alternative treatment histories or newly diagnosed multiple myeloma remain elusive, according to a poster presentation from the Journal of Advanced Practitioner in Oncology conference JADPRO Live (Abstract JL1024E). Therefore, the CARTITUDE trials were implemented to determine the efficacy and safety of the novel CAR T-cell therapy ciltacabtagene autoleucel, explained Ines Stefania Mancia, ARNP, of Memorial Healthcare System, Pembroke Pines, Florida, and colleagues.
A total of 97 patients with multiple myeloma were included in the CARTITUDE-1 trial. Patients were not previously treated with B-cell maturation antigen–targeted or CAR T-cell therapies. Eastern Cooperative Oncology Group scores were calculated; at baseline, patients had scores of 0 (40.2%), 1 (55.7%), and 2 (4.1%). In addition, 99% of patients reported having at least one comorbid condition, including hypertension (45.4%), anemia (49.5%), fatigue (54.6%), and peripheral sensory neuropathy (61.9%). Moreover, laboratory analysis revealed a mean creatinine clearance level of 94.2 mL/min/1.73m2. All patients underwent 12-lead electrocardiograms at screening; 79.4% of patients had normal results, 17.5% had abnormal results that were not considered clinically significant, and 3.1% had abnormal results that were clinically significant. Furthermore, workup with an echocardiogram revealed a mean left-ventricular ejection fraction of 60.8%. These baseline characteristics indicated patients generally have an adequate renal and cardiac function.
“Monitoring of real-world patient characteristics, once ciltacabtagene autoleucel is commercially available, will be important to identify physicians’ prescribing preferences,” the study authors commented.
Disclosure: For full disclosures of the study authors, visit eventscribe.net.
Journal of the Advanced Practitioner in Oncology
JNCCN Spotlights
